Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : NHS England
Deal Size : Undisclosed
Deal Type : Agreement
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK
Details : Vertex has reached a broad reimbursement agreement with NHS England for Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor). It is being indicated for the treatment of Cystic Fibrosis.
Product Name : Alyftrek
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 14, 2025
Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : NHS England
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Deutivacaftor,Tezacaftor,Vanzacaftor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Announces UK MHRA Approval of ALYFTREK for the Treatment of Cystic Fibrosis
Details : Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class CFTR modulator, which is indicated for the treatment of cystic fibrosis.
Product Name : Alyftrek
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2025
Lead Product(s) : Deutivacaftor,Tezacaftor,Vanzacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Gets FDA Acceptance for Vanzacaftor/Tezacaftor/Deutivacaftor for Cystic Fibrosis
Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 02, 2024
Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists
Details : Vanzacaftor is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 08, 2024
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vanzacaftor is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 08, 2024
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Vertex Announces Positive Results from Pivotal Trials for Cystic Fibrosis
Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2024
Lead Product(s) : Vanzacaftor,Deutivacaftor,Tezacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vanzacaftor is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 19, 2023
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vanzacaftor is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VX-121 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 10, 2022
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
Details : VX-121 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 05, 2022
Lead Product(s) : Vanzacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable